Table 1

Baseline characteristics of patients (intent-to-treat population) randomized to receive subcutaneous IFNβ-1a or IFNβ-1b
Baseline characteristic IFNβ-1a (N = 65) IFNβ-1b (N = 64)
Age, years
  Mean (SD) 40.26 (9.80) 40.78 (9.56)
  Median (range) 40.0 (20–60) 40.0 (19–59)
Female, n (%) 46 (70.8) 44 (68.8)
Race, n (%)
  White 55 (84.6) 58 (90.6)
  Black 6 (9.2) 5 (7.8)
  Asian 2 (3.1) 0
  Other 2 (3.1) 1 (1.6)
BMI, kg/m2, mean (SD) 29.66 (6.76) 30.23 (8.35)
Classification of MS, n (%)
  Poser criteria 19 (29.2) 17 (26.6)
  McDonald criteria 46 (70.8) 47 (73.4)
Time since first signs and/or symptoms of MS (onset), years, mean (SD) 4.51 (6.70) 5.74 (6.66)
Time since MS diagnosis, years, mean (SD) 1.01 (2.35) 1.93 (4.02)
Patients with no relapse during the 12 months before informed consent, n (%) 10 (15.4) 14 (21.9)
Relapses per patient,a mean (SD) 1.36 (0.52) 1.30 (0.46)
Time since last relapse,a months, mean (SD) 3.52 (2.94) 4.01 (2.93)
Number of steroid courses required for relapses per patient,a mean (SD) 0.53 (0.60) 0.46 (0.50)
Patients who required ≥1 course of steroids,an (%) 26 (47.3) 23 (46.0)

aBased on total number of patients with relapses during the 12 months before informed consent.

BMI, body mass index; IFN, interferon; MS, multiple sclerosis; SD, standard deviation.

Singer et al.

Singer et al. BMC Neurology 2012 12:154   doi:10.1186/1471-2377-12-154

Open Data